MX1 Price sensitive 28 Aug 2026, 9:43 AM

MX1 - 2026 Appendix 4E and Annual Report

Micro-X Ltd

Micro-X Ltd 2026 Financial Results and Strategic Direction

Key points

  • Revenue increased by 16% to $15,087
  • Loss from ordinary activities decreased by 29% to $(9,876)
  • No dividends declared for FY2026
  • New CEO appointed to lead the company
  • Focus on reducing costs and improving margins

Full summary

Micro-X Ltd, an Australian medical imaging technology company, reported its financial results for the year ended 30 June 2026. The company saw a 16% increase in revenues from ordinary activities, reaching $15,087. However, the loss from ordinary activities after tax decreased by 29% to $(9,876). Despite the improved financial performance, no dividends were paid, recommended, or declared during the financial period. The company has undergone leadership changes, with Dr. Brian Gonzales appointed as the new Chief Executive Officer. Micro-X is now focusing on reducing costs, improving margins, and converting its technical progress into sustainable commercial outcomes.

Guidance

Micro-X Ltd expects to achieve annualized cost savings of more than $3 million in FY27.

Outlook

Micro-X Ltd is focused on converting technical progress into sustainable commercial results, with an emphasis on reducing costs, improving margins, and enhancing product sales.

Sign in for more about this company, including guidance changes and other insights.
Sign in